ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 261

Effect of Advancing Age On the Gastrointestinal Safety of Celecoxib Versus Nonselective Nonsteroidal Anti-Inflammatory Drugs: A Post Hoc Analysis of GI-Reasons

Lee S. Simon1, Byron Cryer2, Gurkirpal Singh3, Chunming Li4 and Margaret Noyes Essex5, 1SDG LLC Consulting, West Newton, MA, 2University of Texas Southwestern Medical Center, Dallas, TX, 3Gastroenterology/Hepatology, Stanford University School of Medicine, Palo Alto, CA, 4Pfizer Inc, New York, NY, 5Pfizer, Inc, New York, NY

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Nonsteroidal antiinflammatory drugs (NSAIDs) and osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Osteoarthritis - Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: Celecoxib use was associated with a lower risk of clinically relevant upper and lower GI events than nonselective (ns)NSAIDs in patients (≥ 55 years) with osteoarthritis (OA) at moderate GI risk, in standard US clinical practice, in the GI Randomized Event and Safety Open-Label NSAID Study (GI-REASONS).1Age has been identified as a factor for increasing patient risk for a GI adverse event when using NSAIDs. The objective was to assess whether the observed decreased GI risk with celecoxib compared to nsNSAIDs varies with advancing age in 8067 patients from the GI-REASONS trial.

Methods: A post hoc analysis of a prospective, randomized, open-label, blinded end point study1 where patients were randomized (1:1) and stratified by H pylori status to receive celecoxib or any nsNSAID for 6 months. Patients randomized to the nsNSAID arm could switch between nsNSAIDS; crossover between treatment arms was not allowed. The primary end point, a composite of investigator and blinded adjudicated clinically significant upper and lower GI events, was assessed according to age (< 60 years, 60-69 years, and ≥ 70 years). Analyses were performed on the intention-to-treat (ITT) population controlling for H pyloristatus.

Results: 4035 celecoxib and 4032 nsNSAID patients with OA were included in the ITT population. 1344 (33.3%) and 1363 (33.8%) were aged < 60 years, 1997 (49.5%) and 1949 (48.3%) were aged 60-69 years, and 688 (17.1%) and 714 (17.7%) were aged ≥ 70 years in the celecoxib and nsNSAID groups, respectively. Age was not specified in 6 patients in both treatment groups. Significantly more patients aged < 60 years and ≥ 70 years in the nsNSAIDs group than in the celecoxib group met the primary end point at 6 months (Table 1). Consistent with the primary results, the most commonly used nsNSAID in each age group was meloxicam. The number of patients using gastric protective agents in the celecoxib and nsNSAID groups were 310 (25.5%) and 335 (27.4%) aged < 60 years, 525 (28.4%) and 517 (28.5%) aged 60-69 years, and 169 (25.8%) and 223 (32.7%) aged ≥ 70 years, respectively. The number of patients who experienced moderate to severe abdominal symptoms in the celecoxib and nsNSAID groups were 37 (2.8%) and 49 (3.6%) aged < 60 years, 40 (2%) and 72 (3.7%) aged 60-69 years, and 17 (2.5%) and 17 (2.4%) aged ≥ 70 years, respectively.

Conclusion: Celecoxib use had a lower risk of clinically significant upper and lower GI events than nsNSAIDs in patients < 60 and ≥ 70 years in the GI-REASONS trial. These data should be considered when prescribing NSAIDs for patients with OA.

Table 1. Clinically Significant Upper and Lower GI Events

 

Celecoxib

nsNSAID

OR (95% CI)

P Value

N

Patients With Event

n (%)

N

Patients With Event

n (%)

< 60 years

1344

13 (1.0)

1363

30 (2.2)

2.3 (1.2-4.3)

0.0120

60-69 years

1997

35 (1.8)

1949

47 (2.4)

1.4 (0.9-2.1)

0.1570

≥ 70 years

688

6 (0.9)

714

21 (2.9)

3.7 (1.5-9.2)

0.0035

Reference: 1. Cryer B, et al. Arthritis Rheum. 2011;63:S777.


Disclosure:

L. S. Simon,

Pfizer Inc, Noven,

5;

B. Cryer,

Pfizer Inc,

5;

G. Singh,

Pfizer Inc,

5;

C. Li,

Pfizer Inc,

3;

M. Noyes Essex,

Pfizer Inc,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-advancing-age-on-the-gastrointestinal-safety-of-celecoxib-versus-nonselective-nonsteroidal-anti-inflammatory-drugs-a-post-hoc-analysis-of-gi-reasons/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology